The US Food and Drug Administration (FDA) has granted approval for Toshiba America Medical Systems’ (TAMS) new Infinix 4DCT with Aquilion Prime CT system configuration.

The new combination includes features and tools that help customers to optimize their time and improve the patient experience, according to Toshiba.

Toshiba vascular business unit director Bill Newsom said: "The Infinix CT allows clinicians to plan, treat and verify in a single clinical setting, which negates the need to transfer patients between departments, resulting in anticipated decreases of both procedure time and risk of infection.

"This also contributes to improved patient safety and satisfaction by minimizing the clinicians’ time spent away from patients, allowing them to focus on providing quality care."

Infinix CT is an all-in-one interventional lab and CT solution, which provides images during procedures instead of CT-like images.

It allows clinicians to carry out CT and interventional procedures within the same room and verify treatment success following procedures.

Capable of providing CT images for the target anatomy, the Infinix CT enhances oncology and cardiac procedures.

Earlier, the Infinix CT obtained FDA approval with the Infinix Elite cardiovascular X-ray system and Aquilion ONE ViSION Edition CT system configuration.

The company will exhibit the new combination at the American College of Cardiology (ACC) annual meeting in San Diego, which is being held from 14 to 16 March.

TAMS develops and markets radiology and cardiovascular systems, including CT, MR, ultrasound, X-ray and cardiovascular equipment.